Future development of new therapeutics targeting AMPK should consider the crosstalk of this kinase with other essential signaling pathways to achieve acceptable efficacy and safety while minimizing unwanted side effects during TB treatment. This evidence concerns the gene PRKAB1 and tuberculosis.